我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

应用64层螺旋CT评价阿托伐他汀治疗效果的价值

《心脏杂志》[ISSN:1009-7236/CN:61-1268/R]

期数:
2015年第2期
页码:
202-205
栏目:
临床研究
出版日期:
2014-10-25

文章信息/Info

Title:
Effect of atorvastatin on computed tomography attenuation value of coronary plaques
作者:
周 逸陈曼华熊才金杨 锴何 琴陈 刚
(武汉市中心医院心血管内科,湖北 武汉 430014)
Author(s):
ZHOU Yi CHEN Man-hua XIONG Cai-jin YANG Kai HE Qin CHEN Gang
(Department of Cardiology, Wuhan Central Hospital, Wuhan 430014, Hubei, China)
关键词:
他汀冠状动脉斑块体层摄影术螺旋计算机
Keywords:
statin coronary plaque tomography spiral computer
分类号:
R445.3
DOI:
-
文献标识码:
A
摘要:
目的:观察应用64层螺旋CT(64-SCT)评价阿托伐他汀治疗效果的价值。方法:回顾性分析阿托伐他汀治疗的36例患者,共计45处非钙化冠脉斑块病变。依据治疗后低密度脂蛋白胆固醇(LDL-C)水平分为达标组(17例,20处病变)和未达标组(19例,25处病变)。比较两组病例血生化指标的变化。比较两组病变血管重构系数、斑块体积、最小管腔直径、斑块平均CT值和最小CT值的变化。结果:达标组LDL-C降幅为47%,大于未达标组的30%(P<0.01)。两组的血管重构系数和斑块体积均可见减小的趋势,但差异均未达到统计学显著水平。与治疗前比较,达标组的斑块平均CT值增加了3.35 Hu(P<0.01),斑块最小CT值升高了10.95 Hu(P<0.01)。未达标组斑块平均CT值及最小CT值均与基线时相似。结论:阿托伐他汀治疗(LDL-C达标)有利于提高冠脉斑块的稳定性。
Abstract:
AIM:To observe the effect of atorvastatin therapy on computed tomography (CT) attenuation value of non-calcified coronary plaques. METHODS: Thirty-six patients with 45 plaques without calcification were analyzed retrospectively. The patients were divided into target-achieving group (17 patients and 20 plaques) and non-target-achieving group (19 patients and 25 plaques) according to the level of low-density lipoprotein cholesterol at follow-up. Changes in serum lipid profile and CT parameters from baseline to follow-up between groups were compared. RESULTS: Reduction of low-density lipoprotein cholesterol in achieving target group and failing to achieve target group were 47% and 30%, respectively. Low-density lipoprotein cholesterol in target-achieving group was significantly lower than that in non-target-achieving group (P<0.01). No significant difference was observed in the changes of remodeling index and plaque volume from baseline to follow-up in both groups. Mean CT attenuation value and minimum CT attenuation value of the coronary plaque increased respectively 3.35 Hu and 10.95 Hu from baseline to follow-up in target-achieving group (P<0.01). Changes of mean CT attenuation value and minimum CT attenuation value of plaques from baseline to follow-up were not significantly different in non-target-achieving group. CONCLUSION: Increase of mean CT attenuation value and minimum CT attenuation value of plaques from baseline to follow-up in target-achieving group may indicate coronary plaque stabilization. Insignificant changes between baseline and follow-up in non-target-achieving group suggest the importance of achieving the therapeutic target of low-density lipoprotein cholesterol.

参考文献/References

[1]Hong YJ,Jeong MH,Hachinohe D,et al.Comparison of effects of rosuvastatin and atorvastatin on plaque regression in Korean patients with untreated intermediate coronary stenosis[J].Circ J,2011,75(2):398-406.
[2]Zhou Y,Chen MH,Yang K,et al.Difference of dilation resistance to coronary stenting between fibrous plaques and lipid-rich plaques[J].Chin Med J,2013,126(21):4149-4153.
[3]European Association for Cardiovascular Prevention & Rehabilitation,Reiner Z,Catapano AL,et al.ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European society of cardiology(ESC)and the European atherosclerosis society (EAS)[J].Eur Heart J,2011,32(14):1769-1818.
[4]Expert Dyslipidemia Panel of the International Atherosclerosis Society Panel Members.An international atherosclerosis society position paper:global recommendations for the management of dyslipidemia--full report[J].J Clin Lipidol,2014,8(1):29-60.
[5]Schoenhagen P,Tuzcu EM,Apperson-Hansen C,et al.Determinants of arterial wall remodeling during lipid-lowering therapy:serial intravascular ultrasound observations from the Reversal of Atherosclerosis with Aggressive Lipid Lowering Therapy (REVERSAL)trial[J].Circulation,2006,113(24):2826-2834.
[6]Nissen SE,Nicholls SJ,Sipahi I,et al.Effect of very high-intensity statin therapy on regression of coronary atherosclerosis:the ASTEROID trial[J].JAMA,2006,295(13):1556-1565.
[7]Ballantyne CM,Raichlen JS,Nicholls SJ,et al.Effect of rosuvastatin therapy on coronary artery stenoses assessed by quantitative coronary angiography:a study to evaluate the effect of rosuvastatin on intravascular ultrasound-derived coronary atheroma burden[J].Circulation,2008,117(19):2458-2466.
[8]Nicholls SJ,Ballantyne CM,Barter PJ,et al.Effect of two intensive statin regimens on progression of coronary disease[J].N Engl J Med,2011,365(22):2078-2087.
[9]Baigent C,Keech A,Kearney PM,et al.Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins[J].Lancet,2005,366(9493):1267-1278.
[10]Motoyama S,Kondo T,Anno H,et al.Atherosclerotic plaque characterization by 0.5-mm-slice multislice computed tomographic imaging[J].Circ J,2007,71(3):363-366.
[11]Hammer-Hansen S,Kofoed KF,Kelbaek H,et al.Volumetric evaluation of coronary plaque in patients presenting with acute myocardial infarction or stable angina pectoris-a multislice computerized tomography study[J].Am Heart J,2009,157(3):481-487.
[12]Hoffmann H,Frieler K,Schlattmann P,et al.Influence of statin treatment on coronary atherosclerosis visualised using multidetector computed tomography[J].Eur Radiol,2010,20(12):2824-2833.
[13]Motoyama S,Sarai M,Harigaya H,et al.Computed tomographic angiography characteristics of atherosclerotic plaques subsequently resulting in acute coronary syndrome[J].J Am Coll Cardiol,2009,54(1):49-57.
[14]Motoyama S, Kondo T, Sarai M, et al. Multislice computed tomographic characteristics of coronary lesions in acute coronary syndromes[J]. J Am Coll Cardiol, 2007, 50(4):319-326.
[15]Kitagawa T, Yamamoto H, Horiguchi J, et al. Characterization of noncalcified coronary plaques and identification of culprit lesions in patients with acute coronary syndrome by 64-slice computed tomography[J].JACC Cardiovasc Imaging, 2009, 2(2):153-160.

备注/Memo

备注/Memo:
收稿日期:2014-06-05.
基金项目:武汉市卫生局临床医学科研项目资助(WX12B03)
通讯作者:陈曼华,主任医师,主要从事冠心病临床及基础研究 Email:chenmh@aliyun.com
作者简介:周逸,副主任医师,硕士 Email:coronary@aliyun.com
更新日期/Last Update: 2014-11-18